Background. Visceral leishmaniasis (VL) is a major public health problem in Bihar, accounting for 90% of all cases in India. Development of high levels of resistance to various existing drugs necessitated the search for alternative orally administered drugs. Hospital-based studies have shown that oral miltefosine is a highly effective treatment for VL both in adults and in children.
ment of VL as it causes irreversible diabetes mellitus [9] . Until recently, amphotericin B [4] has been the most effective drug available in Bihar, but it requires hospitalization of the patient for 4-5 weeks and is relatively toxic. Liposomal amphotericin B (Ambisome) [10] , although effective, is prohibitively costly. Development of oral miltefosine (Impavido) is a historic landmark in the treatment of VL and is highly effective in both adults and children [11] [12] [13] [14] [15] [16] [17] .
Miltefosine is well tolerated with limited side effects that are usually mild and transient (1-2 days) [14, 16, 17] . The drug is contraindicated in pregnancy [18] . Because results in a phase 3 trial among hospitalized patients were excellent, both in terms of efficacy and tolerability, it was felt appropriate to conduct a phase 4 study to evaluate the suitability of miltefosine in an outpatient setting for the kala azar elimination program of the Indian government. The trial was conducted in Bihar with the following objectives: (1) to evaluate the use of miltefosine in patients with confirmed VL in an outpatient setting but with facilities for admission if necessary and (2) to examine whether the high rate of efficacy and low toxicity seen in hospitalized patients can be replicated in an outpatient setting with emphasis on evaluating the ability of peripheral structures to administer it, assessing patient compliance, and determining the acceptability of the drug in this setting. Because use of miltefosine is contraindicated in pregnancy, an attempt was also made to evaluate whether appropriate counseling of female patients of childbearing age and their male partners for avoiding pregnancy by adopting suitable contraception methods in this outpatient setting was feasible.
PATIENTS, MATERIALS, AND METHODS
An open, single-arm trial was designed to address the above objectives in field conditions in 13 centers in Bihar, involving 1135 adult and pediatric patients between 2 and 65 years of age. Most of the centers were private clinics or nursing homes and clinical laboratories, except Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), which is a large government research center solely devoted to research on leishmaniasis. All the clinical investigators were medically qualified physicians having vast experience in treating kala azar patients. The study was done at outpatient department level, and patients with confirmed VL diagnosis were provided with blister strips for medication at home. Only those patients who reported for the adverse events were admitted in the inpatient ward. Most of the patients gave a history of fever of 2 months or more. Severity was assessed on the basis of pallor, spleen and liver size, and laboratory parameters. The study was performed according to Good Clinical and Laboratory Practices. The ethics committees of RMRIMS and the World Health Organization (WHO) approved the study plan. Before study enrollment, written informed consent was obtained from each patient or from the legal guardians of children (in accordance with the Indian Council of Medical Research Guidelines for Biomedical Research). A 3-day training was organized for study personnel. Eligible patients were of either sex between 2 and 65 years of age with a clinical diagnosis of active VL (e.g., fever or splenomegaly) and diagnosis confirmed by splenic aspirate showing characteristic amastigotes. Approximately 10% of patients did not fill eligibility criteria for inclusion in the study for various reasons (e.g., they had malaria; other causes of fever-like tuberculosis, typhoid fever, or urinary tract infection, etc.; or cirrhosis of liver or severe anemia [hemoglobin level !4 g/dL]). Patients with leukocyte count 11000/mm 3 and hemoglobin level у4 g/dL were included. Exclusion criteria were ongoing pregnancy or breast-feeding, refusal to use contraceptive methods during the treatment period and 2 months thereafter (as advised by the clinical investigators), HIV-positive serology, or any condition or situation compromising with compliance to study procedures.
Study medication, dose, mode of administration, and compliance. Miltefosine (10-or 50-mg capsules) packaged in blister strips containing 7 capsules per blister was administered orally daily for 28 days after meals at the following dosages: adults у12 years of age and with a body weight у25 kg received 100 mg in two 50-mg capsules, one in the morning and one in the evening; adults у12 years of age with a body weight !25 kg received 50 mg in one 50-mg capsule in the morning; and children (2-11 years of age) received 2.5 mg/kg in 10-mg capsules in 2 divided doses. Patients were given a 1-week supply of drug at one time, and they were instructed to report every week with the blisters of drugs. Any leftover capsules were counted. In the case of missed doses, a period of up to 35 days was allowed for completion of the treatment course. Clinical evaluation. Patients were assessed weekly during treatment, at the end of treatment, and at follow-up visits 2 months and 6 months after treatment. During each visit, thorough physical examination, adverse event recording, assessment of compliance to drug intake (during treatment), and laboratory tests (blood count and hepatic enzyme, bilirubin, blood urea nitrogen, and creatinine levels at week 2 and 4 and at 2 and 6 months during follow-up) were performed. Parasitological cure was assessed by splenic aspiration at the end of treatment.
Patient guidance under outpatient conditions. Patients were specifically counseled concerning compliance and safety issues under ambulatory conditions. Female patients of "childbearing age" were informed about the unknown risk of "teratogenicity" and the strict requirement of contraception during the treatment period and 2 months thereafter. Enquiry to compliance to contraception was also made during each visit. Patients were carefully instructed about the nature of expected adverse effects (e.g., mild vomiting and diarrhea) and to report any suspected adverse effect.
Criteria for evaluation (efficacy and safety). Efficacy was determined by (1) initial cure (eradication of parasites [0 parasites on splenic aspirate] at the end of treatment or 1+ parasites that became 0 parasites on reaspiration of the spleen at 2 months after the end of treatment); (2) final cure (initial cure and at 6-month posttreatment follow-up the absence of clinical signs and symptoms [splenomegaly or temperature] or abnormality in laboratory parameters attributable to VL or a negative splenic aspirate, if individual signs and symptoms were present); and (3) relapse (initial cure followed by reappearance of clinical signs and symptoms of VL with presence of parasite on splenic aspiration). Safety was assessed by (1) adverse events, (2) clinical signs and symptoms of potential adverse drug reactions, and (3) laboratory evidence of toxicity. Statistical methods. Statistical analysis was performed using an MS Excel-based worksheet (MS Office 2000), WinNonlin Professional Software (Pharsight), and SAS (version 9; SAS Institute).
RESULTS

Patients.
As shown in figure 1, 1135 patients entered into the study. Three patients withdrew, and hence final treatment was started for 1132 patients. Distribution of patients by sex and as adults (у12 years of age) and children (2-11 years of age) are shown in table 1. There were 704 adults and 428 children.
The number of patients who completed the corresponding visits during the treatment phase and posttreatment follow-up period is shown in table 2. In all, 35 (3%) of 1132 patients did not complete 2 weeks of treatment (the minimum duration of treatment that has been shown in previous studies to result in a final cure rate is close to 90%); an additional 16 patients did not complete 3 weeks and 4 weeks of the treatment period. Altogether, 4.5% of patients did not complete the full treatment course, and the dropout rate during treatment was equally distributed among age and sex subgroups. Three patients were unavailable for evaluation because of death. The majority (113) of dropouts were after assessment of initial cure in the posttreatment follow-up period.
Efficacy. Of the 1084 patients who were evaluated between the end of treatment and 2 months thereafter, 1046 had initial cure at the end of treatment. In addition, 9 more patients had 1+ parasites at the end of treatment and had a score of 0 parasites 2 months later (table 3) , giving a total number of 1055 patients who were initially cured. By intention to treat (ITT) analysis, the initial cure rate was 93.2%, referring to 1055 initial cures of 1132 patients who had received at least 1 dose of treatment. Although per protocol analysis showed a higher initial cure rate (1055 [97.3%] initial cures of 1084 patients), this has little relevance in the actual community settings. Another 22 patients were initially cured based on clinical assessment only and without record of splenic aspirate examination (not fulfilling the protocol criteria of initial cure and thus not regarded for initial cure rate).
Mean values of all disease parameters (e.g., temperature, spleen size, body weight, hemoglobin level, white cell count, and platelet count) improved markedly during treatment and continued to normalize during follow-up. Temperature rapidly became normal, usually after 1 week of treatment or, at the latest, after 2 weeks. Splenomegaly regressed rapidly after initiation of treatment as well, and the spleen was not palpable in most patients by the end of treatment.
At the end of the 6-month posttreatment follow-up period, 971 patients were evaluable for final cure (table 3) . Of 927 cured patients, 717 qualified for final cure on the basis of absence of clinical or laboratory signs indicative of kala azar. Tolerability. Miltefosine was well tolerated, and outpatient treatment in the vast majority of patients was safe. Adverse events decreased from 8.2% during week 1 to 3.2% during week 4 (table 4). Diarrhea and vomiting were the predominant symptoms as shown in table 4. When a patient had vomiting and diarrhea, he was listed for both events, because the total number of adverse events was of interest. Of 265 recorded adverse events, 204 patients had clinical complaints, 90 had vomiting, 69 had diarrhea, 15 had other gastrointestinal complaints such as nausea and abdominal pain, 12 reported flulike symptoms, and 18 had other adverse events. A higher degree of gastrointestinal adverse events was rarely reported: 4 patients reported vomiting of common toxicity criteria grade 3 (CTC-3) (in 2 patients at 2 consecutive visits) or CTC-4 (in 1 patient at 2 visits) and 8 patients reported diarrhea of CTC-3 (in 5 patients at 2 consecutive visits) or CTC-4 (in 2 patients at 2 visits).
Three patients died during the treatment phase. One patient died after an episode of acute diarrhea, and another had abdominal pain and swelling both on treatment day 9. One patient died in a car accident.
Of 1132 patients, 13 (1%) were hospitalized during the treatment period (up to 1 week). In 9 patients the events were related to typical adverse effects of miltefosine (higher degree of gastrointestinal adverse events with dehydration and sometimes also with an increase of creatinine of higher grade). One patient having vomiting and diarrhea (CTC-1) missed visit 1 and returned at visit 2 with pneumonia and acute renal failure. One patient each was hospitalized for mouth bleeding, anasarca, disease-related symptoms (raised liver enzymes) at the start of treatment, and, for another patient, reason for hospitalization was not recorded. Further severe adverse event reports included 1 patient each with macular skin rash, epistaxis and hemoptysis, and nausea and vomiting and 2 with undefined events.
Mean values of hepatic and renal parameters decreased during treatment. The mean values of hepatic enzymes, which were slightly elevated at screening, normalized during therapy (table  5) , consistent with the finding of previous inpatient studies. Analysis of treatment-emergent increases of hepatic parameters was similar to previous studies. Elevations were usually mild and transient under therapy with a slight increase at visit 2 and resolution by visit 4 (at the time of highest miltefosine plasma levels). Analysis according to CTC is presented in table 6, giving also explanations on the upper normal limits and CTC grade definitions used for each parameter. In 10% of the study population, CTC-2 elevations and few CTC-3 elevations (∼1%) were observed; all of which were reversible (table 6). There was no indication of a treatment-related bilirubin level increase, with the number of mild elevations nearly negligible (CTC-1 in 11 adults and 1 child and CTC-2 in 1 adult). There was one report of a bilirubin level of 4.7 mg/dL (normal up to 1.0 mg/ dL) together with ascites. Most patients who entered the study with disease-related elevated hepatic enzymes (CTC-1, 559; CTC-2, 221; and CTC-3 39) had significantly improved values at visits after 2 and 4 weeks of treatment. Of 39 patients with CTC-3 elevations at screening, only 2 and 1 patients still had CTC-3 elevations at visits 2 and 4, respectively. Of 221 patients with CTC-2 elevations at screening, only 5 had a deterioration to CTC-3 at visit 2, 39 remained at CTC-2, all others had improved under therapy; at visit 4, 2 had CTC-3 elevations, 22 had CTC-2 elevations, and all others had improved.
Creatinine increase was similar to that of previous studies (table 6 ). An elevation of creatinine, usually mild, was found 19.8% of adults; 14 (2%) of 704 treated adults had CTC-2 elevations, and 7 (1%) of 704 treated adults had CTC-3 elevations. Of the 14 CTC-2 elevations, 8 were in female patients with not more than 1.4 mg/dL (which corresponded to CTC-2 for the female upper normal limit at 0.9 mg/dL in this study).
In the pediatric group, the rate of creatinine increase was significantly lower (10.7%) than in the adult group. CTC-2 elevations were in 4 (0.9%) patients, and there was no CTC-3 elevation. Higher-grade creatinine values were reversible within a short period. Increased values at screening revealed that miltefosine was safe even with CTC-1 and CTC-2 elevations of creatinine. Of 27 patients starting with CTC-2 elevations at screening, none had deteriorated at visit 2, 20 had improved (8 patients to CTC-0 and 12 to CTC-1); at visit 4, a further improvement was seen with only 2 patients who had still CTC-2 elevation and 14 who had returned to normal values (CTC-0). Of 193 CTC-1 elevations at screening, 128 had CTC-0 after 2 weeks of treatment and 1 had deterioration to CTC-2. At visit 4, there were 3 elevations to CTC-2 and 1 to CTC-3 in this group (CTC-1 at screening). Occurrence and outcome of pregnancies. Despite extensive counseling for contraception, 2 cases of pregnancy were reported, with the conception date close to the exposure period. One patient became pregnant 2 weeks after the end of treatment, and the other became pregnant at 3 months after the end of the treatment period. Two healthy babies were delivered at gestational weeks of 39 and 40, without any birth anomaly.
DISCUSSION
In this large phase 4 study, 1084 of 1132 patients completed the full course of miltefosine, and 85.7% patients were available for evaluations at the 6-month posttreatment follow-up. The final cure rate was 81.9% among those who received at least 1 dose of treatment; by per protocol analysis, the cure rate was 95% and was comparable to the cure rate in hospitalized patients [17] . The cure rates of 97% in adults and 94% in children were identical to that observed in studies among hospitalized patients [15, 17] .
It is assumed that most patients who were lost after confirmation of parasite-free splenic aspirate at initial cure assessment were also definitely cured. Relapse rate at final cure assessment was 3.9%, which can be regarded as a valid result because patients were evidently screened thoroughly for failure/relapse. The thoroughness of final evaluation has been demonstrated by the fact that splenic aspirates have been performed in 125% of evaluable patients (254/971) at final cure assessment with a positive finding in 44 (4.5%) only. Splenic aspiration was indicated in all patients who showed at least 1 clinical or laboratory parameter that was possibly also compatible with kala azar. There is good reason to assume that this was a representative result, being probably also correct for the cohort of 113 patients who were lost after being initially cured (by definition of parasite-free splenic aspirate at end of treatment or 2 months thereafter). Therefore, it is thought that the true final cure rate in all patients is indeed rather close to the per protocol cure rate and significantly higher than the ITT cure rate of 82%.
Patient compliance was reasonably good for local conditions of rural Bihar. Most dropouts (∼10% of patients) occurred in the posttreatment follow-up period.
Of the serious adverse events, there were 3 deaths assessed as unrelated to disease or drug and 13 hospitalizations of which the majority were due to diarrhea, vomiting, or dehydration. Further analysis indicated that ∼2% of patients treated with miltefosine would experience clinically significant gastrointestinal adverse effects. Hence, gastrointestinal symptoms have to be recognized as the most common adverse effect due to miltefosine therapy [14, 16, 17] and may limit drug tolerability in some patients, if not anticipated and managed properly.
As observed in previous trials, adverse events were higher during the first week of treatment and progressively diminished by 4 weeks of treatment even though drug levels increased over the time of treatment because of the long half-life of miltefosine (∼7 days) [16] . The decrease in adverse events with time could be due to the progressive resolution of disease activity.
Laboratory testing for monitoring of treatment response (blood count) and safety (hepatic and renal parameters) was performed at screening, after weeks 2 and 4 of treatment, and also during follow-up at 2 and 6 months after treatment, respectively. It has been found that laboratory testing during treatment after week 2 and at the end of treatment is sufficient to meet safety requirements for the large majority of patients. For the majority of patients who had entered with diseaserelated elevated parameters, values normalized during treatment. Even increased screening values of CTC-2 (renal and hepatic) and CTC-3 (hepatic) did not further deteriorate under therapy but were resolved mostly parallel to treatment response.
For hepatic enzymes, transient elevations of moderate degree have been observed in ∼10% of patients of both age groups. Transient increase of creatinine was seen in ∼10% in the pediatric group and in ∼20% in the adult group. In the pediatric group, there were no serious cases, whereas in the adult group there were 7 reports of CTC-3 increases, presumedly as a consequence of dehydration by gastrointestinal adverse effects and/ or concomitant infection (antibiotic therapy). All creatinine increases were reversible, although in one case information is missing. In case of a need for concomitant antibiotic treatment, a closer monitoring of retention parameters might be required.
Based on the finding of teratogenicity of miltefosine in experimental animal (rat) [18] , the drug is contraindicated in pregnancy. Keeping this fact in mind, the present phase 4 study was designed to address this issue amongst the other issues in field conditions. Appropriate counseling of study participants (both females of childbearing age and their male partners) to use suitable contraception during and 2 months after miltefosine treatment was adequate in almost all patients to prevent pregnancy during that period. In spite of this precautionary measure, 2 cases of pregnancy were reported and fortunately both the babies were healthy at birth. However, the anecdotal character of these observations cannot be used to conclude absence of risk.
The oral administration of miltefosine, a safe and effective treatment shown in previous studies including adults and children, has led to new perspectives in the treatment of kala azar. In this study, VL patients were treated, for the first time, in an outpatient setting on a large scale, which required careful adaptation and responsible patient guidance and follow-up by physicians. Not only has a new drug been evaluated in a relatively large outpatient setting but also the finding that the existing structures in Bihar allowed sufficiently safe care under these conditions for a disease that generally necessitates hospitalization for several weeks is a fundamental difference of immense implications. A shift from conservative inpatient treatment to ambulatory care generally for kala azar patients in India would allow simultaneous treatment of many more patients than available hospital capacities. This might be an essential factor for the success of an elimination program. Furthermore, this study is an example of successful public-private partnership to combat a serious infectious disease that largely affects the poor people of the state of Bihar, India.
